Duncan Jarvis

And I suppose that is the kind of question you want the WHO to do to provide some leadership on that.

But not just about treatment, but about things like prevalence, maybe making sure that that testing is effective.

done in a way that actually provides some useful information.

And Helen, you talked to someone who had some concerns about this and who's been quite vocal.

So here's John Ioannidis, Professor in Disease Prevention at Stanford University.

And a way of creating that denominator is with some data.

And in his interview, John mentioned Iceland.

And Helen, you've been busy because, again, you talked to Carrie Stephenson, who is involved in the work there to try and actually test almost the entire population.

He is CEO of Decode Genetics, which is a biopharmaceutical company based

based in Reykjavik.

So this has been a really full, quite an intense COVID-19 podcast.

We've had advice on what to think about when, at the very beginning of this, when people are symptomatic, what are those actual symptoms?

through treatment and what we need to do to actually treat the virus and the evidence to underlie that.

Then we went on to talking about testing and prevalence in the population, which is really important when we're thinking about the models that we use to determine how big this virus is going to go and what kind of measures that need to be in place to prevent that spread.

Through what they're doing in Iceland, where they're trying to get ahead and maybe do some work that could help influence that decision making all around the world.

We're going to be back next week with even more evidence for you, much more on treatment.

And we'll be talking to some people who've been looking, doing a really in-depth look at that.

So you're going to have questions about COVID as everyone else does.

So have a look at bmj.com slash podcast, which where you can find out more.

how to get in touch, and you can let us know what you want to know.